Page last updated: 2024-12-08

cacalol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cacalol: a sesquiterpene contained in Cacalia delphiniifolia Sleb et Zucc; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID181105
CHEMBL ID452935
SCHEMBL ID3134482
MeSH IDM0481628

Synonyms (8)

Synonym
cacalol
(5s)-3,4,5-trimethyl-5,6,7,8-tetrahydrobenzo[f][1]benzofuran-9-ol
CHEMBL452935
24393-79-1
naphtho(2,3-b)furan-9-ol, 5,6,7,8-tetrahydro-3,4,5-trimethyl-, (s)-
SCHEMBL3134482
DTXSID40947263
3,4,5-trimethyl-5,6,7,8-tetrahydronaphtho[2,3-b]furan-9-ol

Research Excerpts

Overview

Cacalol also proved to be a potent neuroprotective substance which could protect neuronal hybridoma N18-RE-105 cells from L-glutamate toxicity.

ExcerptReferenceRelevance
"Cacalol is a sesquiterpene with anti-inflammatory potential that is isolated from"( Cacalol Acetate, a Sesquiterpene from
Alarcón-Aguilar, FJ; Almanza-Pérez, JC; Gomez-Quiroz, LE; Jiménez-Estrada, M; Mora-Ramiro, B; Rosiles-Alanis, W; Ventura-Gallegos, JL; Zentella-Dehesa, A, 2020
)
2.72
"Cacalol also proved to be a potent neuroprotective substance which could protect neuronal hybridoma N18-RE-105 cells from L-glutamate toxicity."( Potent antioxidative activity of cacalol, a sesquiterpene contained in Cacalia delphiniifolia Sleb et Zucc.
Iga, M; Kimura, M; Shindo, K, 2004
)
1.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID380821Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as food intake per mouse at 1000 mg/kg, po administered as single dose1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID359481Antimicrobial activity against Candida albicans ATCC 102312001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID359480Antimicrobial activity against Proteus mirabilis ATCC 124532001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380827Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as body weight per mouse at 1.09 mmol/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID359477Antimicrobial activity against Staphylococcus aureus ATCC 278532001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380819Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as body weight per mouse at 1000 mg/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID380825Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1.09 mmol/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID359482Toxicity against Artemia salina2001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID359478Antimicrobial activity against Escherichia coli ATCC 89372001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380829Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as food intake per mouse at 1.09 mmol/kg, po administered as single dose1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID380817Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1000 mg/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID380816Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1000 mg/kg, po administered as single dose for 3 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID1674505Anti-inflammatory activity in TPA-induced CD-1 mouse ear edema model assessed as inhibition of ear edema at 1 mg relative to control2020Journal of natural products, 08-28, Volume: 83, Issue:8
Cacalol Acetate, a Sesquiterpene from
AID1674504Anti-inflammatory activity in TPA-induced CD-1 mouse ear edema model assessed as ear weight at 1 mg2020Journal of natural products, 08-28, Volume: 83, Issue:8
Cacalol Acetate, a Sesquiterpene from
AID359479Antimicrobial activity against Pseudomonas aeruginosa ATCC 278532001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380824Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1.09 mmol/kg, po administered as single dose for 3 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's6 (54.55)29.6817
2010's3 (27.27)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.09 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]